17 results
Advair (fluticasone propionate and salmeterol)
(fluticasone propionate and salmeterol)GlaxoSmithKline LLC
Usage: ADVAIR DISKUS is indicated for the twice-daily treatment of asthma in patients aged 4 and older, and for the maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It is not intended for the relief of acute bronchospasm.
Advair hfa (fluticasone propionate and salmeterol xinafoate)
(fluticasone propionate and salmeterol xinafoate)GlaxoSmithKline LLC
Usage: ADVAIR HFA is indicated for treating asthma in adults and adolescents (12 years and older) not adequately controlled on long-term asthma medications, specifically when a combination of an inhaled corticosteroid and a long-acting beta2-adrenergic agonist is necessary. It is not for acute bronchospasm relief.
Anoro ellipta (umeclidinium bromide and vilanterol trifenatate)
(umeclidinium bromide and vilanterol trifenatate)GlaxoSmithKline LLC
Usage: ANORO ELLIPTA is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It is not approved for acute bronchospasm relief or asthma treatment, and its safety and effectiveness in asthma remain unestablished.
Arnuity ellipta (fluticasone furoate)
(fluticasone furoate)GlaxoSmithKline LLC
Usage: ARNUITY ELLIPTA is indicated for the maintenance treatment of asthma in adults and pediatric patients aged 5 years and older. It is not intended for the relief of acute bronchospasm.
Benlysta (belimumab)
(belimumab)GlaxoSmithKline LLC
Usage: BENLYSTA (belimumab) is indicated for treating patients aged 5 and older with active systemic lupus erythematosus (SLE) or active lupus nephritis who are on standard therapy. Its efficacy is unproven in severe active central nervous system lupus, and use is not recommended in such cases.
Blujepa (gepotidacin)
(gepotidacin)GlaxoSmithKline LLC
Usage: BLUJEPA is indicated for treating uncomplicated urinary tract infections in females aged 12 years and older, caused by specific susceptible bacteria. It is also recommended to reduce the risk of drug-resistant bacteria by using it only against confirmed or strongly suspected infections from these organisms.
Breo ellipta (fluticasone furoate and vilanterol trifenatate)
(fluticasone furoate and vilanterol trifenatate)GlaxoSmithKline LLC
Usage: BREO ELLIPTA is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma in patients aged 5 years and older. It is not intended for the relief of acute bronchospasm.
Incruse ellipta (umeclidinium)
(umeclidinium)GlaxoSmithKline LLC
Usage: INCRUSE ELLIPTA is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Jalyn (dutasteride and tamsulosin hydrochloride)
(dutasteride and tamsulosin hydrochloride)GlaxoSmithKline LLC
Usage: JALYN (dutasteride and tamsulosin hydrochloride) is indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate. It is not approved for the prevention of prostate cancer.
Jemperli (dostarlimab)
(dostarlimab)GlaxoSmithKline LLC
Usage: JEMPERLI is indicated for adult patients with primary advanced or recurrent endometrial cancer, in combination with carboplatin and paclitaxel, or as a single agent for mismatch repair deficient (dMMR) recurrent or advanced solid tumors that have progressed after prior treatment and lack satisfactory alternatives.